Zymeworks

Valuation Analysis

About the Company

Zymeworks en bref

Zymeworks (ZLAB) is currently trading at 15,87 € with a market capitalization of 1,8 Md €. The 52-week range spans from 13,93 € to 35,95 €; the current price is 55.9% below the yearly high. Year-over-year revenue growth stands at -6.5%.

💰 Dividende

Zymeworks currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

12 analystes évaluent Zymeworks (ZLAB) au consensus : Achat Fort. L'objectif de cours moyen est de 29,06 €, soit un potentiel de +83.19% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 18,85 € à 45,38 €.

Zymeworks : la thèse d'investissement en détail

Zymeworks (ZLAB) operates in the Healthcare — specifically Biotechnology — and is headquartered in China. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 83.19% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -6.5% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 83.19% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (5.93%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Zymeworks?

Compare top-rated brokers — low fees, trusted providers, fully regulated.